Theravance shares fall as late-stage trial for Yupelri fails
mi-viri/iStock via Getty Images Theravance Biopharmacy (NASDAQ: TBPH) lost ~16% premarket on Friday after announcing that Yupelri, its FDA-approved therapy ...
Tag: Yupelri
Recommended.
